Stockreport

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

DaVita Inc.  (DVA) 
Last davita inc. earnings: 2/10 04:01 pm Check Earnings Report
US:NYSE Investor Relations: investors.davita.com/investor-relations
PDF AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receivi [Read more]